Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

A series of pharmaceutical metal complexes (pMCs) were produced and characterized using the mast cell stabilizer, cromolyn, and bioactive metal ions (Zn.sup.+2, Mg.sup.+2, and Ca.sup.+2). Three novel pMCs, Cromolyn-Zn, Cromolyn-Mg, and Cromolyn-Ca were formed through reactions under controlled temperature and pH conditions. TGA demonstrated that these metal complexes showed an enhanced thermal stability due to the strong coordination with the ligand, cromolyn. PXRD data indicates a high degree of crystallinity as well as a unique packing arrangement for each pMCs. SEM analysis showed materials with well-defined morphologies while EDS presented elemental evidence for the unique composition of each pMCs. The crystal structure for these materials was elucidated through SCXRD, and a variety of binding modes and packing motifs were found within each respective metal complex. Only 2D structures were achieved under the conditions studied. Dissolution studies show high stability and slow degradation for the metal complexes, while a higher dissolution was observed for the drug compound in PBS. Neither CS nor the pMCs dissolved significantly in FaSSGF at 37° C.

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.

Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.

Described are edible citrate-rich compositions, including natural juice beverages fortified with natural occurring citrates and synthesized citrate sources that will aid in treatment and prevention of urolithiasis and other urinary tract disorders. Urolithiasis encompasses conditions in which stones are formed or reside in the urinary system and includes nephrolithiasis (stones in the kidneys), ureterolithiasis (stones in the ureter) and cystolithiasis (stones in the bladder)

Described are edible citrate-rich compositions, including natural juice beverages fortified with natural occurring citrates and synthesized citrate sources that will aid in treatment and prevention of urolithiasis and other urinary tract disorders. Urolithiasis encompasses conditions in which stones are formed or reside in the urinary system and includes nephrolithiasis (stones in the kidneys), ureterolithiasis (stones in the ureter) and cystolithiasis (stones in the bladder)

The present invention defines a process for forming a chewable oral dosage form, such as a gum having a pleasant flavor and texture. In particular, the invention includes a process of forming an oral dosage form, comprising: a first step of hydrating a gelling agent of agar-agar and locust bean gum; a second step of mixing in components of the agar matrix; a third step of mixing in an active ingredient; a fourth step of cooking the mixture; a fifth step of flavoring; a sixth step of moulding and gelling; and a seventh step of demoulding, degreasing and drying. The oral dosage form according to the invention also comprises an agar-agar matrix combined with gums, such as locust bean gum, and/or sugar; glycerol; inulin; flavoring agents; citric acid; a coating; and water, to complete the composition, which includes active ingredients.